With FDA's new 'real-time' review, Merck's Keytruda scores paramount nod in lung cancer

21st August 2018 Uncategorised 0

After Merck’s Keytruda-chemo combo demonstrated a mammoth survival advantage back in April, industry watchers fully expected it to win a full approval in previously untreated non-small cell lung cancer. What they may not have expected was how quickly it would happen.

More: With FDA's new 'real-time' review, Merck's Keytruda scores paramount nod in lung cancer
Source: fierce